Our results suggest that the combination of P2Y12 increases the risk of bleeding by 80% and 90%, respectively, compared with ticagrelor and prasugrel, but this does not translate into a worse outcome in patients with MI and CS. Here, P2RY12 is linked to myocardial infarction.